Artemis Therapeutics Inc.
ATMS
Other OTC0.50
USD
-1.39
- -
CIK
0001062128
CUSIP
04302Q109
Return %
Stock
S&P500
1Y
-86.72
18.21
3Y
1,145.00
64.38
5Y
-50.69
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shimon Citron
- Full Time Employees
- 4
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 18 East 16th Street New York City NY United States of America 10003
- IPO Date
- Feb 17, 1998
- CIK
- 0001062128
- Website
- artemis-therapeutics.com
- Similar Companies
- Business
- Artemis Therapeutics Inc. primarily operates through its wholly owned subsidiary, which focuses on the development and distribution of supplements and skincare products. These offerings are formulated with natural components, including Manuka honey and bee venom. The company's business activities shifted significantly following a reverse merger transaction in June 2022, prior to which it was classified as a shell company. Previously, its efforts were directed toward creating treatments for severe infectious diseases. Headquartered in New York, New York, the firm's shares are quoted on the OTC Pink Market under the symbol ATMS.